Related Experiment Video
Updated: May 22, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis
Chen-Ju Lin1, Zeina Nasr, Prem K Premsrirut
1Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada.
Abstract:
The energetically demanding process of translation is linked to multiple signaling events through mTOR-mediated regulation of eukaryotic initiation factor (eIF)4F complex assembly. Disrupting mTOR constraints on eIF4F activity can be oncogenic and alter chemotherapy response, making eIF4F an attractive antineoplastic target. Here, we combine a newly developed inducible RNAi platform and pharmacological targeting of eIF4F activity to define a critical role for endogenous eIF4F in Myc-dependent tumor initiation. We find elevated Myc levels are associated with deregulated eIF4F activity in the prelymphomatous stage of the Emicro-Myc lymphoma model. Inhibition of eIF4F is synthetic lethal with elevated Myc in premalignant pre-B/B cells resulting in reduced numbers of cycling pre-B/B cells and delayed tumor onset. At the organismal level, eIF4F suppression affected a subset of normal regenerating cells, but this was well tolerated and rapidly and completely reversible. Therefore, eIF4F is a key Myc client that represents a tumor-specific vulnerability.
Insights
Targeting eukaryotic initiation factor 4F (eIF4F) shows promise in cancer therapy. Inhibiting eIF4F is synthetically lethal with elevated Myc, a key driver in lymphoma development, offering a tumor-specific vulnerability.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Translation regulation by mTOR controls eukaryotic initiation factor 4F (eIF4F) complex assembly.
- Dysregulated eIF4F activity is implicated in oncogenesis and chemotherapy resistance.
- eIF4F is a potential therapeutic target for antineoplastic strategies.
Purpose of the Study:
- To investigate the role of endogenous eIF4F in Myc-driven tumor initiation.
- To define eIF4F as a critical client of Myc in cancer development.
- To explore the therapeutic potential of targeting eIF4F in Myc-dependent tumors.
Main Methods:
- Utilized a novel inducible RNAi platform for gene manipulation.
- Employed pharmacological agents to target eIF4F activity.
- Studied the Emicro-Myc lymphoma model at prelymphomatous and premalignant stages.
Main Results:
- Elevated Myc levels correlated with deregulated eIF4F activity in premalignant lymphoma cells.
- Inhibition of eIF4F demonstrated synthetic lethality with high Myc levels.
- Suppression of eIF4F reduced cycling premalignant B cells and delayed tumor onset.
- Organismal eIF4F suppression was tolerated in normal regenerating cells and reversible.
Conclusions:
- Endogenous eIF4F plays a critical role in Myc-dependent tumor initiation.
- eIF4F represents a tumor-specific vulnerability exploitable for cancer therapy.
- Targeting eIF4F offers a promising therapeutic strategy for Myc-driven cancers.
Related Concept Videos
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic cells are...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

